ferulic-acid and Venous-Thrombosis

ferulic-acid has been researched along with Venous-Thrombosis* in 1 studies

Other Studies

1 other study(ies) available for ferulic-acid and Venous-Thrombosis

Article	Year
Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate. Bioorganic & medicinal chemistry letters, 2013, Apr-01, Volume: 23, Issue:7 A novel series of prodrugs containing dabigatran and methyl (E)-3-(4-hydroxy-2-methoxyphenyl)propenoate (methyl ferulate) were synthesized. All of them reveal the effect of thrombin-induced anti-platelet aggregation in vitro. In addition, in vivo experiment shows that one of the target compounds, X-2 (ED50=3.7 ± 1.0 μmol/kg) possesses a more potent activity for inhibiting venous thrombosis than that of dabigatran etexilate (ED50=7.8 ± 1.5 μmol/kg). Topics: Benzimidazoles; beta-Alanine; Caffeic Acids; Dabigatran; Dose-Response Relationship, Drug; Drug Design; Fibrinolytic Agents; Humans; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Pyridines; Thrombin; Venous Thrombosis	2013

Article

Year

Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate.

Bioorganic & medicinal chemistry letters, 2013, Apr-01, Volume: 23, Issue:7

A novel series of prodrugs containing dabigatran and methyl (E)-3-(4-hydroxy-2-methoxyphenyl)propenoate (methyl ferulate) were synthesized. All of them reveal the effect of thrombin-induced anti-platelet aggregation in vitro. In addition, in vivo experiment shows that one of the target compounds, X-2 (ED50=3.7 ± 1.0 μmol/kg) possesses a more potent activity for inhibiting venous thrombosis than that of dabigatran etexilate (ED50=7.8 ± 1.5 μmol/kg).

Topics: Benzimidazoles; beta-Alanine; Caffeic Acids; Dabigatran; Dose-Response Relationship, Drug; Drug Design; Fibrinolytic Agents; Humans; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Pyridines; Thrombin; Venous Thrombosis

2013